Phibro Animal Health (NASDAQ:PAHC) CEO Sells $219,562.72 in Stock

Key Points

• Jack Bendheim sold 4,528 shares on May 7 for $219,562.72 under a pre-arranged Rule 10b5‑1 plan, leaving him with 56,152 shares (a 7.46% reduction), and has executed multiple sizable insider sales since March.
• Phibro beat Q3 estimates (EPS $0.76 vs. $0.72; revenue $383.5M vs. $367.0M) and set FY2026 guidance of $2.98–$3.10 EPS (midpoint ~$3.03), while also expanding its revolving credit facility.
• The stock plunged roughly 26.2% to $43.16 on heavy volume amid investor concerns about leverage, even as the company declared a $0.12 quarterly dividend (1.1% yield).

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 4,528 shares of the business's stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $48.49, for a total transaction of $219,562.72. Following the completion of the transaction, the chief executive officer owned 56,152 shares in the company, valued at approximately $2,722,810.48. The trade was a 7.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Bendheim also recently made the following trade(s):

• On Tuesday, May 5th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $55.80, for a total transaction of $392,832.00.
• On Thursday, April 30th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.76, for a total transaction of $371,430.40.
• On Tuesday, April 28th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $55.91, for a total transaction of $393,606.40.
• On Wednesday, April 22nd, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.29, for a total transaction of $382,201.60.
• On Thursday, April 16th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $54.64, for a total transaction of $384,665.60.
• On Tuesday, April 14th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $59.08, for a total transaction of $415,923.20.
• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.52, for a total transaction of $369,740.80.
• On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The shares were sold at an average price of $52.68, for a total transaction of $556,300.80.
• On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.66, for a total transaction of $272,764.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.91, for a total transaction of $258,244.80.

Phibro Animal Health Stock Down 26.2%

PAHC traded down $15.34 during midday trading on Thursday, hitting $43.16. The company had a trading volume of 1,572,579 shares, compared to its average volume of 288,152. Phibro Animal Health Corporation has a 52 week low of $19.17 and a 52 week high of $60.08. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of 19.18, a PEG ratio of 0.86 and a beta of 0.61. The stock's 50 day moving average price is $53.90 and its 200 day moving average price is $46.51.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The firm had revenue of $383.54 million during the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, research analysts anticipate that Phibro Animal Health Corporation will post 3.03 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd will be paid a $0.12 dividend. This represents a $0.48 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, June 3rd. Phibro Animal Health's payout ratio is 21.33%.

Trending Headlines about Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Quarterly results beat expectations — Phibro reported $0.76 EPS vs. $0.72 consensus and revenue of $383.5M vs. $367.0M expected; net sales rose ~10% year-over-year and net income increased ~15%, highlighting continued top-line growth and margin improvement. Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
• Positive Sentiment: Earnings/analyst coverage echoed the beat — multiple outlets and the company transcript highlight the upside vs. estimates, providing evidence the quarter was fundamentally stronger than consensus. Earnings Transcript and Summary
• Neutral Sentiment: FY2026 guidance updated to $2.98–$3.10 EPS and revenue ~ $1.5B (range provided by company). The midpoint is close to analyst expectations (~$3.03), but the range left some uncertainty about the low end. Investors often react to the tone and range width as much as the midpoint. Updated Financial Guidance
• Neutral Sentiment: Dividend declared — company announced a $0.12 quarterly dividend (record June 3, payable June 24), a small yield that supports income-focused holders but is unlikely to materially change valuation. (Company release)
• Neutral Sentiment: Investor events and outreach — management will present at the Bank of America Healthcare Conference next week, offering an opportunity for real-time analyst Q&A and potential clarity on strategy and guidance execution. Conference Participation Announcement
• Neutral Sentiment: Corporate sustainability initiative launched — new VERRATAIN™ sustainability platform and VAXA partnership may improve ESG positioning over time but is unlikely to drive near-term revenue. Sustainability Platform Announcement
• Negative Sentiment: Revolving credit facility expansion raised investor concerns — coverage notes the company expanded its credit line, which some investors read as higher leverage risk or preparation for contingencies; combined with the company’s stated debt/equity profile, this likely increased selling pressure today. Investors Reacting to Revolving Credit Facility Expansion

Wall Street Analyst Weigh In

PAHC has been the subject of several research analyst reports. Citigroup assumed coverage on shares of Phibro Animal Health in a research note on Wednesday, April 15th. They issued a "neutral" rating and a $62.00 price target for the company. Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a research report on Friday, February 6th. Finally, Zacks Research raised shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $42.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its stake in Phibro Animal Health by 3.2% in the first quarter. Dimensional Fund Advisors LP now owns 507,852 shares of the company's stock valued at $28,086,000 after acquiring an additional 15,517 shares during the last quarter. KBC Group NV purchased a new stake in Phibro Animal Health in the 1st quarter worth approximately $29,000. Allspring Global Investments Holdings LLC lifted its stake in Phibro Animal Health by 145.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 286,172 shares of the company's stock worth $15,671,000 after purchasing an additional 169,628 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Phibro Animal Health in the 1st quarter worth approximately $1,759,000. Finally, Advisors Preferred LLC bought a new position in shares of Phibro Animal Health in the 1st quarter worth $2,931,000. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.